Young streak off a low base: a short run of consecutive-period improvement has just started, after a stretch that gave i
The model's full reasoning — Q3 2018 call → NOWe need answer only YES or NO. Need analyze transcript. Question asks: Does management convey that business has now put together short, still-young run of consecutive periods of real improvement roughly 2-4 periods in row of getting better in a part of business that until recently had been giving investors little reason to expect it, and causes attached to company itself and still in force? Need answer based on transcript. We need parse. The transcript includes Q3 2018 earnings. Management discusses financial results. Need identify whether there is a young run of improvement in some part of business. What part? Maybe ARISTADA? VIVITROL? 4230? Or company overall? Let's look for language of consecutive improvement. There is "We continue to see strong growth" etc. But question asks "short, still-young run of consecutive periods of real improvement" in a part that had been unimpressive. Need find. In transcript, management discusses ARISTADA net sales increased 48% year-over-year, 8% sequentially. Growth. But ARISTADA is still growing, not previously unimpressive? It's launch. Maybe "we have seen acceleration in sequential growth of two-month dose, which grew 26% and accounted for 15% in Q3." That's sequential. But not 2-4 periods. VIVITROL net sales increased 15% year-over-year, unit growth 18%, sequentially 5%. Growth. ALKS 5461 not approved. 3831 data upcoming. 4230 early. Maybe "AMPYRA revenues due to delayed generics" not run. Question wording: "NOW PUT TOGETHER A SHORT, STILL-YOUNG RUN OF CONSECUTIVE PERIODS OF REAL IMPROVEMENT — roughly two to four periods in a row of getting better — in a part of the business that, until recently, had been giving investors little reason to expect it" This sounds like specific narrative. Need see if management conveys such. Perhaps regarding 4230? "During the quarter, we initiated our first evaluation ... enrollment now under way." No. Could be regarding "long-acting injectable atypical market" INVEGA SUSTENNA. No. Maybe "Alkermes Plc" overall: Previously losses? They now have non-GAAP net income positive? Q3 non-GAAP net income $11.6 million. Full year improved.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OLPX | Olaplex Holdings, Inc. | Q4 2023 | 2024-02-29 | D |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LEG | Leggett & Platt, Incorporated | Q3 2021 | 2021-11-02 | C |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
WRBY · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
ASB · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
KOPN · Q4 2023 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...